Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 18, 2000

View Archived Issues

FDA clears new dose of Concerta for ADHD

Cytochroma collaborates with Johns Hopkins on vitamin D-related drug discovery

EntreMed commences phase I trial of Angiostatin by s.c. injection

Forest reports successful completion of phase III escitalopram clinical trial

Guilford seeks E.U. approval to begin trials of novel anesthetic and analgesic agents

British Biotech updates product development programs

First-in-class antithrombotic demonstrates benefits over comparators in preventing DVT

Amgen finalizes Kinetix acquisition

FDA approves pediatric indication for Tamiflu

Schering-Plough seeks additional FDA approval for Rebetol capsules

Another major merger announced

AeroGen begins phase II clinical trials with AeroDose insulin inhaler

Pharmacia returns rights to glaucoma diagnostic to InSite Vision

Anti-TNF-alpha MAb effective against spondyloarthropathy associated with Crohn's disease

Novel Yamanouchi compound activates gene expression, translocation of Glut4

Orally active HNE inhibitor in clinical trials at Ono

New antiretroviral Kaletra granted positive opinion in E.U.

Arzoxifene has identical effects to tamoxifen in endometrial cancer models

S-1 appears to safely improve survival in metastatic breast cancer patients

Nortran's phase II clinical trial of CP1 fails to meet primary endpoint

Potent MMP inhibitor delays osteolytic disease associated with breast cancer metastasis

Large group of MEK-inhibitory quinolines discovered at AstraZeneca

Inhibitors of Lp-PLA2 and their use in atherosclerosis described by SB in recent patent

Merck Frosst synthesizes potent, selective and orally active PDE4 inhibitors

Two series of inhibitors of alpha4beta1-mediated cell adhesion claimed by Aventis

Vitamin D-like effects discovered in novel Roche compounds

Dipeptide caspase, apoptosis inhibitors designed by Cytovia research team

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...